JPWO2019226941A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019226941A5 JPWO2019226941A5 JP2020565312A JP2020565312A JPWO2019226941A5 JP WO2019226941 A5 JPWO2019226941 A5 JP WO2019226941A5 JP 2020565312 A JP2020565312 A JP 2020565312A JP 2020565312 A JP2020565312 A JP 2020565312A JP WO2019226941 A5 JPWO2019226941 A5 JP WO2019226941A5
- Authority
- JP
- Japan
- Prior art keywords
- sequence
- antigen
- nucleic acid
- mhc class
- optionally
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 55
- 150000007523 nucleic acids Chemical group 0.000 claims 51
- 239000000427 antigen Substances 0.000 claims 41
- 108091007433 antigens Proteins 0.000 claims 41
- 102000036639 antigens Human genes 0.000 claims 41
- 102000043129 MHC class I family Human genes 0.000 claims 38
- 108091054437 MHC class I family Proteins 0.000 claims 38
- 239000000203 mixture Substances 0.000 claims 26
- 239000002773 nucleotide Substances 0.000 claims 26
- 125000003729 nucleotide group Chemical group 0.000 claims 26
- 239000013598 vector Substances 0.000 claims 23
- 108091034057 RNA (poly(A)) Proteins 0.000 claims 15
- 239000008194 pharmaceutical composition Substances 0.000 claims 15
- 206010028980 Neoplasm Diseases 0.000 claims 12
- 102000043131 MHC class II family Human genes 0.000 claims 11
- 108091054438 MHC class II family Proteins 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 11
- 108090000623 proteins and genes Proteins 0.000 claims 11
- 235000001014 amino acid Nutrition 0.000 claims 10
- 229960005486 vaccine Drugs 0.000 claims 10
- 241000700605 Viruses Species 0.000 claims 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 7
- 238000000338 in vitro Methods 0.000 claims 7
- 238000000034 method Methods 0.000 claims 7
- 238000013518 transcription Methods 0.000 claims 7
- 230000035897 transcription Effects 0.000 claims 7
- 108700028369 Alleles Proteins 0.000 claims 6
- 230000003321 amplification Effects 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 238000003199 nucleic acid amplification method Methods 0.000 claims 6
- 229920001184 polypeptide Polymers 0.000 claims 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims 5
- 241000178568 Aura virus Species 0.000 claims 4
- 241000231322 Fort Morgan virus Species 0.000 claims 4
- 241000710960 Sindbis virus Species 0.000 claims 4
- 108090000848 Ubiquitin Proteins 0.000 claims 4
- 102000044159 Ubiquitin Human genes 0.000 claims 4
- 201000011510 cancer Diseases 0.000 claims 4
- 206010014599 encephalitis Diseases 0.000 claims 4
- 239000002955 immunomodulating agent Substances 0.000 claims 4
- 229940121354 immunomodulator Drugs 0.000 claims 4
- 230000001404 mediated effect Effects 0.000 claims 4
- 235000018102 proteins Nutrition 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 241000710929 Alphavirus Species 0.000 claims 3
- 108020004414 DNA Proteins 0.000 claims 3
- 241000608292 Mayaro virus Species 0.000 claims 3
- 102000004245 Proteasome Endopeptidase Complex Human genes 0.000 claims 3
- 108090000708 Proteasome Endopeptidase Complex Proteins 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 230000001939 inductive effect Effects 0.000 claims 3
- 230000001225 therapeutic effect Effects 0.000 claims 3
- 210000001519 tissue Anatomy 0.000 claims 3
- 210000004881 tumor cell Anatomy 0.000 claims 3
- 239000003981 vehicle Substances 0.000 claims 3
- 101710094648 Coat protein Proteins 0.000 claims 2
- 230000006820 DNA synthesis Effects 0.000 claims 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 claims 2
- 102100036242 HLA class II histocompatibility antigen, DQ alpha 2 chain Human genes 0.000 claims 2
- 101000930801 Homo sapiens HLA class II histocompatibility antigen, DQ alpha 2 chain Proteins 0.000 claims 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 2
- 102000018697 Membrane Proteins Human genes 0.000 claims 2
- 108010052285 Membrane Proteins Proteins 0.000 claims 2
- 241000710942 Ross River virus Species 0.000 claims 2
- 241000710961 Semliki Forest virus Species 0.000 claims 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 2
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims 2
- 235000004279 alanine Nutrition 0.000 claims 2
- 125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- -1 amino lipid Chemical class 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 230000002584 immunomodulator Effects 0.000 claims 2
- 210000003712 lysosome Anatomy 0.000 claims 2
- 230000001868 lysosomic effect Effects 0.000 claims 2
- 230000035772 mutation Effects 0.000 claims 2
- 239000013612 plasmid Substances 0.000 claims 2
- 238000000746 purification Methods 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 229960000814 tetanus toxoid Drugs 0.000 claims 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 2
- UNIKQYIJSJGRRS-UHFFFAOYSA-N 2-(dimethylazaniumyl)butanoate Chemical compound CCC(N(C)C)C(O)=O UNIKQYIJSJGRRS-UHFFFAOYSA-N 0.000 claims 1
- 108020005345 3' Untranslated Regions Proteins 0.000 claims 1
- 108020003589 5' Untranslated Regions Proteins 0.000 claims 1
- OGHAROSJZRTIOK-FCIPNVEPSA-O 7-methylguanosine Chemical compound C1=2N=C(N)NC(=O)C=2[N+](C)=CN1[C@@H]1O[C@@H](CO)[C@H](O)[C@H]1O OGHAROSJZRTIOK-FCIPNVEPSA-O 0.000 claims 1
- 241001217856 Chimpanzee adenovirus Species 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 108091035707 Consensus sequence Proteins 0.000 claims 1
- 108060003951 Immunoglobulin Proteins 0.000 claims 1
- 108010029660 Intrinsically Disordered Proteins Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 108091092878 Microsatellite Proteins 0.000 claims 1
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 claims 1
- 101800000515 Non-structural protein 3 Proteins 0.000 claims 1
- 108700026244 Open Reading Frames Proteins 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 101800000980 Protease nsP2 Proteins 0.000 claims 1
- 108010076504 Protein Sorting Signals Proteins 0.000 claims 1
- 108010065868 RNA polymerase SP6 Proteins 0.000 claims 1
- 101800001758 RNA-directed RNA polymerase nsP4 Proteins 0.000 claims 1
- 101710172711 Structural protein Proteins 0.000 claims 1
- 108091027544 Subgenomic mRNA Proteins 0.000 claims 1
- 101710137500 T7 RNA polymerase Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 210000000234 capsid Anatomy 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 210000004443 dendritic cell Anatomy 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 claims 1
- 230000002519 immonomodulatory effect Effects 0.000 claims 1
- 230000028993 immune response Effects 0.000 claims 1
- 230000005847 immunogenicity Effects 0.000 claims 1
- 102000018358 immunoglobulin Human genes 0.000 claims 1
- 238000003780 insertion Methods 0.000 claims 1
- 230000037431 insertion Effects 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 claims 1
- 238000002955 isolation Methods 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002105 nanoparticle Substances 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 238000002205 phenol-chloroform extraction Methods 0.000 claims 1
- 230000008488 polyadenylation Effects 0.000 claims 1
- 238000012545 processing Methods 0.000 claims 1
- 238000005215 recombination Methods 0.000 claims 1
- 230000006798 recombination Effects 0.000 claims 1
- 239000000377 silicon dioxide Substances 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 238000006467 substitution reaction Methods 0.000 claims 1
- 230000032258 transport Effects 0.000 claims 1
- 235000002374 tyrosine Nutrition 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024153547A JP2024178211A (ja) | 2018-05-23 | 2024-09-06 | 共有抗原 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862675559P | 2018-05-23 | 2018-05-23 | |
| US201862675649P | 2018-05-23 | 2018-05-23 | |
| US62/675,559 | 2018-05-23 | ||
| US62/675,649 | 2018-05-23 | ||
| PCT/US2019/033830 WO2019226941A1 (en) | 2018-05-23 | 2019-05-23 | Shared antigens |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024153547A Division JP2024178211A (ja) | 2018-05-23 | 2024-09-06 | 共有抗原 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021525076A JP2021525076A (ja) | 2021-09-24 |
| JPWO2019226941A5 true JPWO2019226941A5 (https=) | 2022-05-27 |
| JP2021525076A5 JP2021525076A5 (https=) | 2022-05-27 |
| JP7554119B2 JP7554119B2 (ja) | 2024-09-19 |
Family
ID=68617213
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020565312A Active JP7554119B2 (ja) | 2018-05-23 | 2019-05-23 | 共有抗原 |
| JP2024153547A Pending JP2024178211A (ja) | 2018-05-23 | 2024-09-06 | 共有抗原 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024153547A Pending JP2024178211A (ja) | 2018-05-23 | 2024-09-06 | 共有抗原 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20210196806A1 (https=) |
| EP (1) | EP3796927A4 (https=) |
| JP (2) | JP7554119B2 (https=) |
| KR (1) | KR20210013105A (https=) |
| CN (1) | CN112368386A (https=) |
| AU (2) | AU2019275072A1 (https=) |
| CA (1) | CA3099644A1 (https=) |
| IL (1) | IL278864B1 (https=) |
| TW (1) | TW202000907A (https=) |
| WO (1) | WO2019226941A1 (https=) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102643923B1 (ko) | 2014-12-23 | 2024-03-05 | 이매틱스 바이오테크놀로지스 게엠베하 | 간세포 암종(hcc) 및 기타 암들에 대한 면역요법에서의 사용을 위한 신규 펩티드 및 펩티드의 조합 |
| GB201501017D0 (en) | 2014-12-23 | 2015-03-04 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers |
| GB201505305D0 (en) | 2015-03-27 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel Peptides and combination of peptides for use in immunotherapy against various tumors |
| ES2983924T3 (es) | 2015-03-27 | 2024-10-28 | Immatics Biotechnologies Gmbh | Péptidos novedosos y combinación de péptidos para usarse en inmunoterapia contra diferentes tumores |
| GB201604458D0 (en) | 2016-03-16 | 2016-04-27 | Immatics Biotechnologies Gmbh | Peptides and combination of peptides for use in immunotherapy against cancers |
| DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| IL280890B2 (en) * | 2018-08-17 | 2025-10-01 | Gritstone Bio Inc | Antigen-binding protein that targets shared antigens |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| WO2020186064A1 (en) * | 2019-03-12 | 2020-09-17 | The General Hospital Corporation | Highly networked immunogen composition |
| MX2021014525A (es) | 2019-05-30 | 2022-03-17 | Gritstone Bio Inc | Adenovirus modificados. |
| DE102019114735A1 (de) * | 2019-06-02 | 2020-12-03 | PMCR GmbH | HLA-Tumorantigenpeptiden der Klasse I und II zur Behandlung von Mamma-/Brustkarzinomen |
| AU2020384374A1 (en) * | 2019-11-15 | 2022-06-09 | Seattle Project Corp. | Antigen-binding proteins targeting shared neoantigens |
| KR20220115569A (ko) | 2019-11-18 | 2022-08-17 | 얀센 바이오테크 인코포레이티드 | 돌연변이 calr 및 jak2에 기반한 백신 및 이의 용도 |
| EP4062177A1 (en) * | 2019-11-18 | 2022-09-28 | Epivax Therapeutics, Inc. | Improved compositions and methods for shared neo-epitope vaccines |
| WO2021119545A1 (en) * | 2019-12-11 | 2021-06-17 | Gritstone Bio, Inc. | Durable vaccination |
| AU2021258191A1 (en) * | 2020-04-21 | 2022-12-01 | Seattle Project Corp. | Antigen-encoding cassettes |
| US12312412B2 (en) | 2020-05-19 | 2025-05-27 | Amgen Inc. | MAGEB2 binding constructs |
| US12295997B2 (en) | 2020-07-06 | 2025-05-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| KR20230046313A (ko) | 2020-08-06 | 2023-04-05 | 그릿스톤 바이오, 인코포레이티드 | 다중에피토프 백신 카세트 |
| JP2023541671A (ja) * | 2020-09-17 | 2023-10-03 | プロシーナ バイオサイエンシーズ リミテッド | シヌクレイノパチーの処置のためのアルファ－シヌクレインワクチン |
| CN116710115A (zh) | 2020-11-20 | 2023-09-05 | 思维疗法股份有限公司 | 用于优化的肽疫苗的组合物和方法 |
| US11421015B2 (en) | 2020-12-07 | 2022-08-23 | Think Therapeutics, Inc. | Method of compact peptide vaccines using residue optimization |
| US11058751B1 (en) | 2020-11-20 | 2021-07-13 | Think Therapeutics, Inc. | Compositions for optimized RAS peptide vaccines |
| WO2022120217A2 (en) * | 2020-12-03 | 2022-06-09 | Gritstone Bio, Inc. | Homologous adenoviral vaccination |
| CN112852841A (zh) * | 2021-02-03 | 2021-05-28 | 郑州大学 | 一种高效表达目的蛋白的顺式复制子rna构建体 |
| WO2022171032A1 (zh) * | 2021-02-10 | 2022-08-18 | 上海吉倍生物技术有限公司 | Ras G13D突变体表位肽及识别Ras G13D突变体的T细胞受体 |
| MX2023012141A (es) * | 2021-04-14 | 2023-11-28 | Tscan Therapeutics Inc | Peptidos inmunogenicos magec2, proteinas de union que reconocen peptidos inmunogenicos magec2, y usos de estos. |
| US11464842B1 (en) | 2021-04-28 | 2022-10-11 | Think Therapeutics, Inc. | Compositions and method for optimized peptide vaccines using residue optimization |
| CA3216276A1 (en) | 2021-04-29 | 2022-11-03 | Yardena Samuels | T cell receptors directed against ras-derived recurrent neoantigens and methods of identifying same |
| TWI804229B (zh) * | 2021-09-27 | 2023-06-01 | 美商圖策智能科技有限公司 | 基於蛋白質突變預測的蛋白質結合自由能估測方法及系統 |
| CN115785205B (zh) * | 2022-06-10 | 2024-08-30 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标09及其用途 |
| CN115785208B (zh) * | 2022-06-10 | 2024-07-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标01及其用途 |
| CN115785211B (zh) * | 2022-06-10 | 2024-09-24 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标04及其用途 |
| CN115785206B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标07及其用途 |
| CN115785207B (zh) * | 2022-06-10 | 2024-08-30 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标02及其用途 |
| CN115785209B (zh) * | 2022-06-10 | 2024-08-02 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标06及其用途 |
| CN115785204B (zh) * | 2022-06-10 | 2024-02-13 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标08及其用途 |
| CN115785203B (zh) * | 2022-06-10 | 2024-03-12 | 河北博海生物工程开发有限公司 | 肺癌特异性分子靶标10及其用途 |
| JP2025542192A (ja) * | 2022-12-23 | 2025-12-25 | ハンミ ファーマシューティカルズ カンパニー リミテッド | 複数のｋｒａｓ変異ペプチドが連結された抗原ペプチド、それをコーディングする核酸、及びその用途 |
| CN116183907B (zh) * | 2023-03-09 | 2025-03-25 | 巴迪泰（广西）生物科技有限公司 | 一种基于抗原捕捉磁珠技术的抗原富集与清洗方法及系统 |
| WO2024216073A1 (en) * | 2023-04-14 | 2024-10-17 | The Trustees Of Columbia University In The City Of New York | Engineered microbes comprising tumor neoantigen vectors for cancer immunotherapy |
| WO2024254461A2 (en) * | 2023-06-07 | 2024-12-12 | Nutech Ventures | Methods and compositions for vaccine development and delivery |
| GB202400424D0 (en) * | 2024-01-11 | 2024-02-28 | Cancer Research Tech Ltd | Treatment and prevention of lung cancer |
| WO2025153053A1 (en) * | 2024-01-17 | 2025-07-24 | Abogen Biosciences (Shanghai) Co., Ltd. | Composition and methods for inducing antigen specific immunity against kras mutant cells |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| GB8311018D0 (en) | 1983-04-22 | 1983-05-25 | Amersham Int Plc | Detecting mutations in dna |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| FR2650840B1 (fr) | 1989-08-11 | 1991-11-29 | Bertin & Cie | Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications |
| US5240846A (en) | 1989-08-22 | 1993-08-31 | The Regents Of The University Of Michigan | Gene therapy vector for cystic fibrosis |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| US6004744A (en) | 1991-03-05 | 1999-12-21 | Molecular Tool, Inc. | Method for determining nucleotide identity through extension of immobilized primer |
| PT728214E (pt) | 1993-11-09 | 2004-11-30 | Ohio Med College | Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado |
| WO1996013597A2 (en) | 1994-10-28 | 1996-05-09 | The Trustees Of The University Of Pennsylvania | Improved adenovirus and methods of use thereof |
| US5792462A (en) * | 1995-05-23 | 1998-08-11 | University Of North Carolina At Chapel Hill | Alphavirus RNA replicon systems |
| US5849589A (en) | 1996-03-11 | 1998-12-15 | Duke University | Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells |
| ATE220718T1 (de) * | 1996-04-19 | 2002-08-15 | Us Gov Sec Health | Mutierte ras peptide zur zeugung von cd8+ zytitoxischen t lymphoizyten |
| WO1998010087A1 (en) | 1996-09-06 | 1998-03-12 | Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
| MXPA02006554A (es) | 1999-12-28 | 2003-09-22 | Epimmune Inc | Minigenes optimizados y peptidos codificados por los mismos. |
| US20040248113A1 (en) * | 1999-12-28 | 2004-12-09 | Alessandro Sette | Method and system for optimizing multi-epitope nucleic acid constructs and peptides encoded thereby |
| US7462354B2 (en) * | 1999-12-28 | 2008-12-09 | Pharmexa Inc. | Method and system for optimizing minigenes and peptides encoded thereby |
| EP2311950A1 (en) * | 2000-01-28 | 2011-04-20 | The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services | Novel MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1 |
| WO2004031210A2 (en) * | 2002-10-03 | 2004-04-15 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| WO2005033265A2 (en) * | 2003-04-25 | 2005-04-14 | Epimmune Inc. | Optimized multi-epitope constructs and uses thereof |
| ATE449105T1 (de) * | 2004-01-23 | 2009-12-15 | Angeletti P Ist Richerche Bio | Impfstoffträger für schimpansen-adenovirus |
| US7332322B2 (en) * | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| US7220549B2 (en) | 2004-12-30 | 2007-05-22 | Helicos Biosciences Corporation | Stabilizing a nucleic acid for nucleic acid sequencing |
| US7283337B2 (en) | 2005-03-04 | 2007-10-16 | Headway Technologies, Inc. | Abutted exchange bias design for sensor stabilization |
| CN101579528B (zh) | 2009-06-24 | 2011-06-29 | 中国人民解放军军事医学科学院军事兽医研究所 | 一种hiv复合多表位dna疫苗及其应用 |
| BR112012029066A2 (pt) | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| KR20190002733A (ko) | 2010-12-30 | 2019-01-08 | 파운데이션 메디신 인코포레이티드 | 종양 샘플의 다유전자 분석의 최적화 |
| TWI775117B (zh) * | 2013-08-05 | 2022-08-21 | 德商伊瑪提克斯生物科技有限公司 | 新穎肽類，細胞及其用於治療多種腫瘤的用途，其製造方法及包含其等之醫藥組成物（二） |
| TW202523682A (zh) * | 2015-05-20 | 2025-06-16 | 美商博德研究所有限公司 | 共有之gata3相關之腫瘤特異性新抗原 |
| RU2729116C2 (ru) * | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| KR20190020098A (ko) * | 2016-06-20 | 2019-02-27 | 아이에스에이 파마슈티컬즈 비.브이. | 펩타이드 백신의 제형 |
| PE20191345A1 (es) * | 2016-11-23 | 2019-09-30 | Gritstone Oncology Inc | Administracion viral de neoantigenos |
| GB201621732D0 (en) * | 2016-12-20 | 2017-02-01 | Agricultural Research Council | A multi-epitope dna vaccine for heartwater |
| KR102841050B1 (ko) | 2017-04-19 | 2025-08-01 | 그릿스톤 바이오, 인코포레이티드 | 신생항원 동정, 제조, 및 용도 |
| MX2019013259A (es) | 2017-05-08 | 2020-01-13 | Gritstone Oncology Inc | Vectores de neoantigeno de alfavirus. |
| CN110720127A (zh) * | 2017-06-09 | 2020-01-21 | 磨石肿瘤生物技术公司 | 新抗原的鉴别、制造及使用 |
-
2019
- 2019-05-23 CN CN201980034786.XA patent/CN112368386A/zh active Pending
- 2019-05-23 KR KR1020207036368A patent/KR20210013105A/ko active Pending
- 2019-05-23 WO PCT/US2019/033830 patent/WO2019226941A1/en not_active Ceased
- 2019-05-23 EP EP19808088.9A patent/EP3796927A4/en active Pending
- 2019-05-23 US US17/058,128 patent/US20210196806A1/en active Pending
- 2019-05-23 CA CA3099644A patent/CA3099644A1/en active Pending
- 2019-05-23 JP JP2020565312A patent/JP7554119B2/ja active Active
- 2019-05-23 AU AU2019275072A patent/AU2019275072A1/en not_active Abandoned
- 2019-05-23 IL IL278864A patent/IL278864B1/en unknown
- 2019-05-23 TW TW108117933A patent/TW202000907A/zh unknown
-
2024
- 2024-09-06 JP JP2024153547A patent/JP2024178211A/ja active Pending
-
2026
- 2026-01-16 AU AU2026200326A patent/AU2026200326A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPWO2019226941A5 (https=) | ||
| JP2021525076A5 (https=) | ||
| JP7554119B2 (ja) | 共有抗原 | |
| US20230270841A1 (en) | Coronavirus vaccine | |
| JP2021524247A5 (https=) | ||
| EP3177720B1 (en) | Virus like particle comprising modified envelope protein e3 | |
| RU2019119272A (ru) | Вирусная доставка неоантигенов | |
| JP2021524247A (ja) | 免疫チェックポイント阻害剤の共発現ベクター | |
| JP2022512912A (ja) | アルファウイルス新生抗原ベクター及びインターフェロン阻害因子 | |
| JP2021501572A5 (https=) | ||
| EP3423473A2 (en) | Virus vectors expressing multiple epitopes of tumor associated antigens for inducing antitumor immunity | |
| JPWO2021236854A5 (https=) | ||
| JP2003520597A (ja) | 組換えフラビウイルスおよびその使用方法 | |
| BR112015023524B1 (pt) | Vírus vaccinia ankara modificado, composição compreendendo o dito vírus e uso do mesmo para primagem ou reforço de uma resposta imune | |
| CN114854773A (zh) | 顺式复制子构建体 | |
| CN106459997A (zh) | 用于疫苗应用的高效价病毒样囊泡的进化 | |
| JP2004501646A5 (https=) | ||
| JP2020532287A (ja) | 癌の治療のためのネオアンチゲンワクチン組成物 | |
| JPWO2019226939A5 (https=) | ||
| EP4175721A1 (en) | Prostate neoantigens and their uses | |
| JPWO2020097393A5 (https=) | ||
| JPWO2022032196A5 (https=) | ||
| JPWO2020243719A5 (https=) | ||
| WO2025002153A1 (zh) | 树突状细胞靶向的类病毒体dvlp及其制备方法和应用 | |
| JPWO2021003348A5 (https=) |